
Marcio Nucci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9511225/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). Haematologica, 2023, 108, 22-33.	3.5	15
2	Evaluation of a stewardship program of antifungal use at a Brazilian tertiary care hospital. Brazilian Journal of Infectious Diseases, 2022, 26, 102333.	0.6	4
3	Ecthyma gangrenosum in neutropenic patients and the importance of an early skin scraping for direct examination. Anais Brasileiros De Dermatologia, 2022, 97, 534-534.	1.1	0
4	Phylogenomic Analysis of a 55.1-kb 19-Gene Dataset Resolves a Monophyletic <i>Fusarium</i> that Includes the <i>Fusarium solani</i> Species Complex. Phytopathology, 2021, 111, 1064-1079.	2.2	107
5	Anti-Sporothrix activity of ibuprofen combined with antifungal. Brazilian Journal of Microbiology, 2021, 52, 101-106.	2.0	9
6	Increased incidence of candidemia in a tertiary care hospital with the COVIDâ€19 pandemic. Mycoses, 2021, 64, 152-156.	4.0	114
7	(1,3)â€Î²â€Dâ€glucan is able to predict therapeutic failure of patients with candidemia and not only mortality. Mycoses, 2021, 64, 264-271.	4.0	1
8	Do high MICs predict the outcome in invasive fusariosis?. Journal of Antimicrobial Chemotherapy, 2021, 76, 1063-1069.	3.0	28
9	Epidemiology of invasive fungal disease in haematologic patients. Mycoses, 2021, 64, 252-256.	4.0	28
10	Fusarium and Fusariosis. , 2021, , .		2
11	Improving awareness of several combination therapies for acute myeloid leukemia among oncology and hematology team members in Colorado, USA. Hematology, Transfusion and Cell Therapy, 2021, , .	0.2	0
12	How I treat febrile neutropenia. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021025.	1.3	8
13	Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease. World Journal of Gastroenterology, 2021, 27, 866-885.	3.3	2
14	EQUAL Fusariosis Score 2021: An European Confederation of Medical Mycology score derived from current guidelines to measure QUALity of the clinical management of invasive fusariosis. Mycoses, 2021, 64, 1542-1545.	4.0	6
15	Trends towards lower azole susceptibility among 200 Candida tropicalis bloodstream isolates from Brazilian medical centres. Journal of Global Antimicrobial Resistance, 2021, 25, 199-201.	2.2	4
16	Epidemiology of Invasive Fungal Diseases in Patients with Hematologic Malignancies and Hematopoietic Cell Transplantation Recipients Managed with an Antifungal Diagnostic Driven Approach. Journal of Fungi (Basel, Switzerland), 2021, 7, 588.	3.5	17
17	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infectious Diseases, The. 2021, 21, e246-e257.	9.1	167
18	Early versus Late Fluconazole Prophylaxis in Autologous Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 681.e1-681.e5.	1.2	1

#	Article	IF	CITATIONS
19	When to change treatment of acute invasive aspergillosis: an expert viewpoint. Journal of Antimicrobial Chemotherapy, 2021, 77, 16-23.	3.0	15
20	Invasive Fusariosis in Patients with Hematologic Diseases. Journal of Fungi (Basel, Switzerland), 2021, 7, 815.	3.5	22
21	Invasive Fusariosis in Nonneutropenic Patients, Spain, 2000–2015. Emerging Infectious Diseases, 2021, 27, 24-36.	4.3	19
22	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	17.0	189
23	Is Early Invasive Pulmonary Aspergillosis Coming of Age?. Clinical Infectious Diseases, 2020, 70, 347-347.	5.8	3
24	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
25	COVID â€19 infection in patients with Sézary syndrome: Report of two cases. Dermatologic Therapy, 2020, 33, e14042.	1.7	5
26	Baseline Chest Computed Tomography as Standard of Care in High-Risk Hematology Patients. Journal of Fungi (Basel, Switzerland), 2020, 6, 36.	3.5	15
27	<i>β</i> –1,6-linked Galactofuranose- rich peptidogalactomannan of <i>Fusarium oxysporum</i> is important in the activation of macrophage mechanisms and as a potential diagnostic antigen. Medical Mycology, 2019, 57, 234-245.	0.7	7
28	Shock and Early Death in Hematologic Patients with Febrile Neutropenia. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	20
29	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	9.1	970
30	Antimicrobial Drug Prophylaxis: Challenges and Controversies. , 2019, , 1123-1135.		0
31	Mucormycosis in South America: A review of 143 reported cases. Mycoses, 2019, 62, 730-738.	4.0	39
32	Performance of 1,3â€betaâ€Dâ€glucan in the diagnosis and monitoring of invasive fusariosis. Mycoses, 2019, 62, 570-575.	4.0	25
33	Molecular Characterization and Antifungal Susceptibility of Clinical Fusarium Species From Brazil. Frontiers in Microbiology, 2019, 10, 737.	3.5	49
34	Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis?. Mycoses, 2019, 62, 413-417.	4.0	18
35	Effect of circadian variation on neutrophil mobilization to the peripheral blood in benign constitutional neutropenia. Experimental Hematology, 2019, 69, 22-26.	0.4	11
36	Rhodotorula infection in haematological patient: Risk factors and outcome. Mycoses, 2019, 62, 223-229.	4.0	17

#	Article	IF	CITATIONS
37	Time of catheter removal in candidemia and mortality. Brazilian Journal of Infectious Diseases, 2018, 22, 455-461.	0.6	13
38	Cryptococcosis in Patients with Hematologic Diseases. Current Fungal Infection Reports, 2018, 12, 187-194.	2.6	2
39	Secular trends of candidemia at a Brazilian tertiary care teaching hospital. Brazilian Journal of Infectious Diseases, 2018, 22, 273-277.	0.6	19
40	Prevention of Infections in Patients with Hematological Malignancies. , 2018, , 1047-1062.		6
41	Typhlitis (neutropenic enterocolitis) in patients with acute leukemia: a review. Expert Review of Hematology, 2017, 10, 169-174.	2.2	24
42	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. Intensive Care Medicine, 2017, 43, 509-518.	8.2	51
43	Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials. Journal of Antimicrobial Chemotherapy, 2017, 72, 2368-2377.	3.0	24
44	Anidulafungin for the treatment of candidaemia caused by <i>Candida parapsilosis</i> : Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, 60, 663-667.	4.0	16
45	Daunorubicin 90 mg/m 2 in Acute Myeloid Leukemia Induction: Increased Toxicity in YoungÂPatients. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 527-531.	0.4	5
46	Respiratory Tract Infection Caused by Fonsecaea monophora After Kidney Transplantation. Mycopathologia, 2017, 182, 1101-1109.	3.1	4
47	Antimold Prophylaxis May Reduce the Risk of Invasive Fusariosis in Hematologic Patients with Superficial Skin Lesions with Positive Culture for Fusarium. Antimicrobial Agents and Chemotherapy, 2016, 60, 7290-7294.	3.2	26
48	Diagnostic-driven antifungal therapy in neutropenic patients using the D-index and serial serum galactomannan testing. Brazilian Journal of Infectious Diseases, 2016, 20, 354-359.	0.6	7
49	Discontinuation of empirical antifungal therapy in ICU patients using 1,3-β-d-glucan. Journal of Antimicrobial Chemotherapy, 2016, 71, 2628-2633.	3.0	56
50	Invasive fungal diseases in patients with acute lymphoid leukemia. Leukemia and Lymphoma, 2016, 57, 2084-2089.	1.3	22
51	Acute Paracoccidioidomycosis Due to Paracoccidioides brasiliensis S1 Mimicking Hypereosinophilic Syndrome with Massive Splenomegaly: Diagnostic Challenge. PLoS Neglected Tropical Diseases, 2016, 10, e0004487.	3.0	13
52	Effect of the implosion and demolition of a hospital building on the concentration of fungi in the air. Mycoses, 2015, 58, 707-713.	4.0	10
53	Evaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapy. Diagnostic Pathology, 2015, 10, 122.	2.0	4
54	Infections After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. , 2015, , 49-61.		3

#	Article	IF	CITATIONS
55	Tackling antibiotic resistance in febrile neutropenia: current challenges with and recommendations for managing infections with resistant Gram-negative organisms. Expert Review of Hematology, 2015, 8, 647-658.	2.2	15
56	Combination Antifungal Therapy for Invasive Aspergillosis. Annals of Internal Medicine, 2015, 162, 81-89.	3.9	376
57	Fusariosis. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 706-714.	2.1	75
58	Distinguishing the Causes of Pulmonary Infiltrates in Patients With Acute Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S98-S103.	0.4	11
59	Risk Factors for Invasive Fusariosis in Patients With Acute Myeloid Leukemia and in Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2015, 60, 875-880.	5.8	56
60	Susceptibility of Sporothrix brasiliensis isolates to amphotericin B, azoles, and terbinafine. Medical Mycology, 2015, 53, 178-188.	0.7	88
61	Feasibility and Outcome of the Hyper-CVAD Regimen in Patients With Adult Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 52-57.	0.4	12
62	Earlier Diagnosis of Invasive Fusariosis with Aspergillus Serum Galactomannan Testing. PLoS ONE, 2014, 9, e87784.	2.5	79
63	Surveillance of Candida spp Bloodstream Infections: Epidemiological Trends and Risk Factors of Death in Two Mexican Tertiary Care Hospitals. PLoS ONE, 2014, 9, e97325.	2.5	30
64	1211A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Invasive Aspergillosis Patients. Open Forum Infectious Diseases, 2014, 1, S37-S37.	0.9	4
65	Interaction between IL-6 and TNF-α genotypes associated with bacteremia in multiple myeloma patients submitted to autologous stem cell transplantation (ASCT). Leukemia Research Reports, 2014, 3, 76-78.	0.4	3
66	An openâ€label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in <scp>L</scp> atin <scp>A</scp> merica. Mycoses, 2014, 57, 12-18.	4.0	17
67	Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Medicine, 2014, 40, 1489-1498.	8.2	150
68	Active Surveillance of Candidemia in Children from Latin America. Pediatric Infectious Disease Journal, 2014, 33, e40-e44.	2.0	65
69	Efficacy of micafungin in invasive candidiasis caused by common <i>Candida</i> species with special emphasis on nonâ€ <i>albicans Candida</i> species. Mycoses, 2014, 57, 79-89.	4.0	15
70	Diagnosis of Candidemia. Current Fungal Infection Reports, 2014, 8, 90-94.	2.6	7
71	Conference Report from the 6th Trends in Medical Mycology Meeting, Copenhagen, 11–14 October 2013: Facing the Global Threat of Fungal Disease. Current Fungal Infection Reports, 2014, 8, 116-118.	2.6	1
72	Superficial skin lesions positive for Fusarium are associated with subsequent development of invasive fusariosis. Journal of Infection, 2014, 68, 85-89.	3.3	57

#	Article	IF	CITATIONS
73	How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach. Blood, 2014, 124, 3858-3869.	1.4	62
74	Less Graft-Versus-Host Disease after Rabbit Antithymocyte Globulin Conditioning in Unrelated Bone Marrow Transplantation for Leukemia and Myelodysplasia: Comparison with Matched Related Bone Marrow Transplantation. PLoS ONE, 2014, 9, e107155.	2.5	8
75	Molecular analyses of Fusarium isolates recovered from a cluster of invasive mold infections in a Brazilian hospital. BMC Infectious Diseases, 2013, 13, 49.	2.9	50
76	Epidemiology of Fusariosis. Current Fungal Infection Reports, 2013, 7, 301-305.	2.6	17
77	Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance. BMC Infectious Diseases, 2013, 13, 356.	2.9	52
78	Brazilian guidelines for the management of candidiasis – a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical. Brazilian Journal of Infectious Diseases, 2013, 17, 283-312.	0.6	100
79	Early diagnosis of invasive pulmonary aspergillosis in hematologic patients: an opportunity to improve the outcome. Haematologica, 2013, 98, 1657-1660.	3.5	57
80	Recommendations for the management of candidemia in adults in Latin America. Revista Iberoamericana De Micologia, 2013, 30, 179-188.	0.9	29
81	Recommendations for the management of candidemia in children in Latin America. Revista Iberoamericana De Micologia, 2013, 30, 171-178.	0.9	13
82	<i>Candida glabrata</i> : an emerging pathogen in Brazilian tertiary care hospitals. Medical Mycology, 2013, 51, 38-44.	0.7	47
83	Prevention of Infections in Patients with Hematological Malignancies. , 2013, , 1149-1164.		1
84	Increased Incidence of Invasive Fusariosis with Cutaneous Portal of Entry, Brazil. Emerging Infectious Diseases, 2013, 19, 1567-1572.	4.3	88
85	Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica, 2013, 98, 79-86.	3.5	132
86	Epidemiology of Candidemia in Latin America: A Laboratory-Based Survey. PLoS ONE, 2013, 8, e59373.	2.5	267
87	Baseline Platelet Count and Creatinine Clearance Rate Predict the Outcome of Neutropenia-Related Invasive Aspergillosis. Clinical Infectious Diseases, 2012, 54, e173-e183.	5.8	23
88	Reply to Bergeron et al. Clinical Infectious Diseases, 2012, 55, 476-477.	5.8	0
89	The role of antifungal treatment in hematology. Haematologica, 2012, 97, 325-327.	3.5	60
90	Epidemiology and predictors of a poor outcome in elderly patients with candidemia. International Journal of Infectious Diseases, 2012, 16, e442-e447.	3.3	50

#	Article	IF	CITATIONS
91	Different Outcomes between Cyclophosphamide Plus Horse or Rabbit Antithymocyte Globulin for HLA-Identical Sibling Bone Marrow Transplant in Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2012, 18, 1876-1882.	2.0	28
92	Brazilian guidelines for the management of candidiasis: a joint meeting report of three medical societies – Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia, Sociedade Brasileira de Medicina Tropical. Brazilian Journal of Infectious Diseases, 2012, 16, S1-S34.	0.6	2

#	Article	IF	CITATIONS
109	Recomendações no manejo das complicações infecciosas no transplante de células-tronco hematopoéticas. Revista Brasileira De Hematologia E Hemoterapia, 2010, 32, 140-162.	0.7	5
110	Reply to Koh and Luong and to Shaked et al. Clinical Infectious Diseases, 2010, 51, 1348-1350.	5.8	1
111	Probable Invasive Aspergillosis without Prespecified Radiologic Findings: Proposal for Inclusion of a New Category of Aspergillosis and Implications for Studying Novel Therapies. Clinical Infectious Diseases, 2010, 51, 1273-1280.	5.8	109
112	Early Removal of Central Venous Catheter in Patients with Candidemia Does Not Improve Outcome: Analysis of 842 Patients from 2 Randomized Clinical Trials. Clinical Infectious Diseases, 2010, 51, 295-303.	5.8	202
113	Candidemia Surveillance in Brazil: Evidence for a Geographical Boundary Defining an Area Exhibiting an Abatement of Infections by <i>Candida albicans</i> Group 2 Strains. Journal of Clinical Microbiology, 2010, 48, 3062-3067.	3.9	10
114	Epidemiology of Opportunistic Fungal Infections in Latin America. Clinical Infectious Diseases, 2010, 51, 561-570.	5.8	209
115	D-index and Prediction of Infection. Biology of Blood and Marrow Transplantation, 2010, 16, 1608.	2.0	4
116	Infecciones fúngicas emergentes. Annales Nestlé (Ed Española), 2009, 67, 135-142.	0.1	0
117	Hyalohyphomycosis. , 2009, , 309-327.		14
118	Invasive fungal infections in cancer patients. , 2009, , 431-471.		11
119	Infections in Patients with Multiple Myeloma in the Era of Highâ€Dose Therapy and Novel Agents. Clinical Infectious Diseases, 2009, 49, 1211-1225.	5.8	297
120	Index to Predict Invasive Mold Infection in High-Risk Neutropenic Patients Based on the Area Over the Neutrophil Curve. Journal of Clinical Oncology, 2009, 27, 3849-3854.	1.6	102
121	A Multicenter, Doubleâ€Blind Trial of a Highâ€Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis. Clinical Infectious Diseases, 2009, 48, 1676-1684.	5.8	196
122	Paracoccidioidomycosis. Current Fungal Infection Reports, 2009, 3, 15.	2.6	27
123	Brazilian Experience Using High-Dose Sequential Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma. Clinical Lymphoma and Myeloma, 2009, 9, 449-454.	1.4	4
124	Infections in Patients With Multiple Myeloma. Seminars in Hematology, 2009, 46, 277-288.	3.4	41
125	Fungal Infections in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation—Focus on Aspergillosis. Clinics in Chest Medicine, 2009, 30, 295-306.	2.1	28
126	Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, phaeohyphomycosis and chromoblastomycosis. Current Opinion in Infectious Diseases, 2009, 22, 559-563.	3.1	56

#	Article	IF	CITATIONS
127	Emerging Fungal Infections. Annales Nestle, 2009, 67, 133-139.	0.1	Ο
128	Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood, 2009, 114, 1270-1275.	1.4	85
129	Infections fongiques émergentes. Annales Nestle [Ed Francaise], 2009, 67, 135-142.	0.0	0
130	Optimising the Use of Non-invasive Tests: From Blood to Radiology. , 2009, , 407-422.		0
131	When Primary Antifungal Therapy Fails. Clinical Infectious Diseases, 2008, 46, 1426-1433.	5.8	77
132	Evidence for a Pseudo-Outbreak of Candida guilliermondii Fungemia in a University Hospital in Brazil. Journal of Clinical Microbiology, 2007, 45, 942-947.	3.9	27
133	Candidemia due to Candida tropicalis: clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals. Diagnostic Microbiology and Infectious Disease, 2007, 58, 77-82.	1.8	100
134	Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet, The, 2007, 369, 1519-1527.	13.7	1,185
135	Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis. Clinical Infectious Diseases, 2007, 45, 883-893.	5.8	1,115
136	<i>Fusarium</i> Infections in Immunocompromised Patients. Clinical Microbiology Reviews, 2007, 20, 695-704.	13.6	813
137	Antifungal Drug Susceptibility Profile of Pichia anomala Isolates from Patients Presenting with Nosocomial Fungemia. Antimicrobial Agents and Chemotherapy, 2007, 51, 1573-1576.	3.2	31
138	A prospective randomized trial to reduce oral Candida spp. colonization in patients with hyposalivation. Brazilian Oral Research, 2007, 21, 182-187.	1.4	28
139	Invasive Mold Infections. Infectious Disease and Therapy, 2007, , 171-220.	0.0	1
140	Emerging Fungi. Infectious Disease Clinics of North America, 2006, 20, 563-579.	5.1	58
141	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. Clinical Infectious Diseases, 2006, 43, 1031-1039.	5.8	3
142	Clinical and microbiological aspects of candidemia due toCandida parapsilosisin Brazilian tertiary care hospitals. Medical Mycology, 2006, 44, 261-266.	0.7	65
143	Epidemiology of Candidemia in Brazil: a Nationwide Sentinel Surveillance of Candidemia in Eleven Medical Centers. Journal of Clinical Microbiology, 2006, 44, 2816-2823.	3.9	387
144	Variations of salivary flow rates in Brazilian school children. Brazilian Oral Research, 2006, 20, 8-12.	1.4	12

#	Article	IF	CITATIONS
145	Hypermethylation of DAP-K Is an Adverse Prognostic Factor in Patients with Multiple Myeloma (MM) Blood, 2006, 108, 2220-2220.	1.4	0
146	Epidemiologia, tratamento e profilaxia das infecções na leucemia linfóide crônica. Revista Brasileira De Hematologia E Hemoterapia, 2005, 27, 290.	0.7	3
147	A non-randomized comparative study using different doses of acyclovir to prevent herpes simplex reactivation in patients submitted to autologous stem cell transplantation. Brazilian Journal of Infectious Diseases, 2005, 9, 330-5.	0.6	6
148	Risk Factors for Acquisition of Multidrug-Resistant Pseudomonas aeruginosa Producing SPM Metallo-β-Lactamase. Antimicrobial Agents and Chemotherapy, 2005, 49, 3663-3667.	3.2	53
149	Prothrombin 20210A and Oral Contraceptive Use as Risk Factors for Cerebral Venous Thrombosis. Cerebrovascular Diseases, 2005, 19, 49-52.	1.7	50
150	Candidemia in Patients with Cancer: Are Persistent Neutropenia and Severity of Illness Score Still Relevant?. Clinical Infectious Diseases, 2005, 40, 1063-1064.	5.8	4
151	Emerging Fungal Diseases. Clinical Infectious Diseases, 2005, 41, 521-526.	5.8	358
152	High-Dose Sequential Chemotherapy Versus a Less Intensive Chemotherapeutic Regimen Followed by Peripheral Blood Progenitor Cell Autografting in Patients with Advanced Hodgkin's Disease Blood, 2005, 106, 5485-5485.	1.4	0
153	Allogeneic Peripheral Blood Stem Cell Transplants (PBSCT) May Have a Benefit in Acute Lymphoblastic Leukemia (ALL) Outcome Blood, 2005, 106, 1136-1136.	1.4	0
154	Fusarium Infection in Hematopoietic Stem Cell Transplant Recipients. Clinical Infectious Diseases, 2004, 38, 1237-1242.	5.8	300
155	Successful treatment of oral lesions of chronic lichenoid graft-vshost disease by the addition of low-level laser therapy to systemic immunosuppression. European Journal of Haematology, 2004, 72, 222-224.	2.2	18
156	Outcome predictors of 84 patients with hematologic malignancies andFusariuminfection. Cancer, 2003, 98, 315-319.	4.1	270
157	Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Current Opinion in Infectious Diseases, 2003, 16, 607-612.	3.1	144
158	Nosocomial Outbreak ofExophiala jeanselmeiFungemia Associated with Contamination of Hospital Water. Clinical Infectious Diseases, 2002, 34, 1475-1480.	5.8	68
159	Should Vascular Catheters Be Removed from All Patients with Candidemia? An Evidence-Based Review. Clinical Infectious Diseases, 2002, 34, 591-599.	5.8	174
160	Cutaneous Infection by <i>Fusarium</i> Species in Healthy and Immunocompromised Hosts: Implications for Diagnosis and Management. Clinical Infectious Diseases, 2002, 35, 909-920.	5.8	374
161	Relationship between salivary flow rates and Candida counts in subjects with xerostomia. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2002, 93, 149-154.	1.4	151
162	Emergence of resistant Candida in neutropenic patients. Brazilian Journal of Infectious Diseases, 2002, 6, 124-8.	0.6	13

#	Article	IF	CITATIONS
163	Risk Factors for Breakthrough Candidemia. European Journal of Clinical Microbiology and Infectious Diseases, 2002, 21, 209-211.	2.9	82
164	Resistant bacteria in stem cell transplant recipients. Revista Brasileira De Hematologia E Hemoterapia, 2002, 24, .	0.7	1
165	Application of the IDSA Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients: Impact on Reducing the Use of Glycopeptides. Infection Control and Hospital Epidemiology, 2001, 22, 651-653.	1.8	26
166	Emergence of black moulds in fungal disease: epidemiology and therapy. Current Opinion in Infectious Diseases, 2001, 14, 679-684.	3.1	87
167	Can we decrease amphotericin nephrotoxicity?. Current Opinion in Critical Care, 2001, 7, 379-383.	3.2	30
168	Application of an adapted international prognostic index for aggressive non-Hodgkin's lymphomas: Good discrimination and lower survival rates in Rio de Janeiro, Brazil. Oncology Reports, 2001, 8, 441.	2.6	1
169	Clinical significance of Aspergillus fungaemia in patients with haematological malignancies and invasive aspergillosis. British Journal of Haematology, 2001, 114, 93-98.	2.5	39
170	Revisiting the Source of Candidemia: Skin or Gut?. Clinical Infectious Diseases, 2001, 33, 1959-1967.	5.8	359
171	Nosocomial Fungemia Due to Exophiala jeanselmei var. jeanselmei and a Rhinocladiella Species: Newly Described Causes of Bloodstream Infection. Journal of Clinical Microbiology, 2001, 39, 514-518.	3.9	62
172	Fungal infections in the immunocompromised host. Memorias Do Instituto Oswaldo Cruz, 2000, 95, 153-158.	1.6	27
173	Epidemiology of Bloodstream Infections at a Cancer Center. Sao Paulo Medical Journal, 2000, 118, 131-138.	0.9	29
174	Thiabendazole for the Treatment of Strongyloidiasis in Patients with Hematologic Malignancies. Clinical Infectious Diseases, 2000, 31, 821-822.	5.8	21
175	Mixed Infection Caused by Two Species ofFusarium in a Human Immunodeficiency Virus-Positive Patient. Journal of Clinical Microbiology, 2000, 38, 3460-3462.	3.9	39
176	Comparison of the Toxicity of Amphotericin B in 5% Dextrose with That of Amphotericin B in Fat Emulsion in a Randomized Trial with Cancer Patients. Antimicrobial Agents and Chemotherapy, 1999, 43, 1445-1448.	3.2	53
177	High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagnostic Microbiology and Infectious Disease, 1999, 34, 281-286.	1.8	157
178	Predictive value of a positive nasal swab for Aspergillus SP. in the diagnosis of invasive aspergillosis in adult neutropenic cancer patients. Diagnostic Microbiology and Infectious Disease, 1999, 35, 193-196.	1.8	5
179	<i>Phialemonium</i> Fungemia: Two Documented Nosocomial Cases. Journal of Clinical Microbiology, 1999, 37, 2493-2497.	3.9	40
180	Fungemia in cancer patients in Brazil: predominance of non-albicans species. Mycopathologia, 1998, 141, 65-68.	3.1	25

#	Article	IF	CITATIONS
181	Risk Factors for Death Among Cancer Patients with Fungemia. Clinical Infectious Diseases, 1998, 27, 107-111.	5.8	72
182	Resistance to Activated Protein C in Thrombophilic Patients in Rio de Janeiro. Acta Haematologica, 1998, 100, 113-113.	1.4	0
183	Risk Factors for Death in Patients with Candidemia. Infection Control and Hospital Epidemiology, 1998, 19, 846-850.	1.8	137
184	Risk Factors for Death in Patients with Candidemia. Infection Control and Hospital Epidemiology, 1998, 19, 846-850.	1.8	91
185	Clinical Factors Predictive of Bone Marrow Involvement in Hodgkin's Disease. Leukemia and Lymphoma, 1997, 26, 171-176.	1.3	14
186	Spinal Cord Compression due to Extramedullary Hematopoiesis in the Proliferative Phase of Polycythemia vera. Acta Haematologica, 1996, 96, 242-244.	1.4	25
187	Randomized Trial Comparing Oral Ciprofloxacin Plus Penicillin V with Amikacin Plus Carbenicillin or Ceftazidime for Empirical Treatment of Febrile Neutropenic Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 1995, 18, 429-435.	1.3	33
188	Antibiotic regimen as an independent risk factor for disseminated fungal infections in neutropenic patients in Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 107-110.	1.8	8
189	Fungal infections in neutropenic patients: a 8-year prospective study. Revista Do Instituto De Medicina Tropical De Sao Paulo, 1995, 37, 397-406.	1.1	32
190	Ceftazidime and amikacin as empirical treatment of febrile episodes in neutropenic patients. Journal of Infection, 1994, 28, 335-336.	3.3	3
191	C-MOPP/ABV yields good results in a public hospital population with Hodgkin disease in Brazil. Cancer, 1993, 71, 2823-2827.	4.1	15
192	Low-Grade Lymphoma Following Intensive Treatment of Large-Cell Lymphoma. Acta Haematologica, 1993, 90, 48-51.	1.4	3
193	Intensified ABVP chemotherapy for the primary treatment of Hodgkin's disease. Oncology Reports, 0, , .	2.6	Ο